West Pharma Surges on Biologics Demand | Business and Finance News

West Pharmaceutical Services is soaring with a blockbuster Q2, smashing revenue and earnings forecasts with $872.3M in sales—up 13% year-over-year—thanks to booming demand for high-value biologics and biosimilar components. Driven by global regulatory shifts like Europe’s Annex 1 and surging GLP-1 therapies for diabetes and obesity, the company’s leadership is doubling down, raising full-year guidance and crediting resilient operations that bounced back from a cyberattack. With new drug launches on the horizon and strategic margin improvements, West is not just weathering the storm—it’s riding the wave of innovation and demand toward sustained growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7dcccb74b106c019